Document Detail


Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin.
MedLine Citation:
PMID:  8382133     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. Elevation of blood pressure is one of the major side effects of recombinant human erythropoietin therapy in haemodialysis patients. 2. We investigated the possible involvement of endothelin in the pathogenesis of this recombinant human erythropoietin-induced blood pressure elevation in 51 patients undergoing maintenance haemodialysis. 3. Blood haemoglobin level increased from 7.1 +/- 0.1 to 8.8 +/- 0.1 g/dl (means +/- SEM) after 8 weeks of treatment with recombinant human erythropoietin (3000-4500 units/week). An increase in mean blood pressure was found in 19 patients (37%) (n = 9, by 0-10 mmHg; n = 10, by > 10 mmHg). 4. Plasma immunoreactive-endothelin concentration significantly increased from 2.26 +/- 0.18 to 3.14 +/- 0.31 pmol/l in the 10 patients whose mean blood pressure increased by more than 10 mmHg (P < 0.05), but not in the other patients. Moreover, the increase in plasma immunoreactive-endothelin concentration showed a significant positive correlation with the change in mean blood pressure in 19 patients with elevated mean blood pressure (r = 0.47, P < 0.05). 5. There was no significant correlation between the change in plasma immunoreactive-endothelin concentration and the change in blood haemoglobin level or the change in body weight. 6. These results suggest the possibility that endothelin may contribute to the recombinant human erythropoietin-related rise in blood pressure in some haemodialysis patients.
Authors:
K Takahashi; K Totsune; Y Imai; M Sone; M Nozuki; O Murakami; H Sekino; T Mouri
Related Documents :
6272003 - Hypotensive response to angiotensin ii analogue and angiotensin i converting enzyme inh...
6400373 - Role of cardiopulmonary receptors in reflex control of renin release in man.
15063403 - Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-indu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical science (London, England : 1979)     Volume:  84     ISSN:  0143-5221     ISO Abbreviation:  Clin. Sci.     Publication Date:  1993 Jan 
Date Detail:
Created Date:  1993-03-25     Completed Date:  1993-03-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7905731     Medline TA:  Clin Sci (Lond)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  47-50     Citation Subset:  IM    
Affiliation:
Second Department of Internal Medicine, Tohoku University School of Medicine, Miyagi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Pressure / drug effects
Endothelins / blood*
Erythropoietin / therapeutic use*
Hemoglobins / analysis
Humans
Kidney Failure, Chronic / blood*,  therapy
Middle Aged
Recombinant Proteins / therapeutic use
Renal Dialysis
Chemical
Reg. No./Substance:
0/Endothelins; 0/Hemoglobins; 0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Renal and systemic sympathetic counterregulation in response to vasodilators in renovascular hyperte...
Next Document:  Possible link between vitamin D and hyperoxaluria in patients with renal stone disease.